Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

14 Jul 2010 09:18

RNS Number : 3215P
Hutchison China Meditech Limited
14 July 2010
 



For filings with the FSA include the annex

For filings with issuer exclude the annex

 

TR-1: notification of major interests in shares i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

HUTCHISON CHINA MEDITECH LTD

 

2. Reason for the notification (please tick the appropriate box or boxes) :

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: iii

 

Slater Investments Ltd

 

4. Full name of shareholder(s)  (if different from

3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

 

12 July 2010

6. Date on which issuer notified:

 

13 July 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

 

Over 7%

 

1.

1. 1. 1.

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

 

if possible using the ISIN CODE

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B11Y2X4

3,228,165

3,228,165

2,126,769

2,126,769

1,619,000

3.11%

4.11%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion Period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,745,769

7.24%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 

Nicola Smith

15. Contact telephone number:

 

+44 20 7330 6130

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUSAWRRNABARR
Date   Source Headline
31st Mar 20207:04 amRNSChina Phase II trial initiation in mesothelioma
25th Mar 20207:00 amRNSAnnual Financial Report
9th Mar 20207:00 amRNSVesting of awards under Long Term Incentive Plan
3rd Mar 20202:18 pmRNSForm-20F Publication
3rd Mar 202012:15 pmRNSFinal Results and Clinical Update
25th Feb 20207:00 amRNSNotice of Results
10th Feb 20207:00 amRNSPhase II Savolitinib / Imfinzi® Combination Data
6th Feb 20204:35 pmRNSPrice Monitoring Extension
6th Feb 20207:20 amRNSIssue of Equity
4th Feb 20204:40 pmRNSSecond Price Monitoring Extn
4th Feb 20204:35 pmRNSPrice Monitoring Extension
31st Jan 20207:00 amRNSNotice of Results
29th Jan 20207:25 amRNSHolding(s) in Company
23rd Jan 20207:35 amRNSPricing of US$110 Million Public Offering of ADSs
22nd Jan 20207:00 amRNSChi-Med Announces Proposed Offering of ADSs
20th Jan 202010:40 amRNSPositive SANET-p Phase III Clinical Trial Results
13th Jan 20207:00 amRNSChi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
6th Jan 20207:04 amRNSChi-Med to Present at JP Morgan Conference
31st Dec 20197:00 amRNSBlock Listing Six Monthly Return
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20197:00 amRNSSurufatinib Granted Priority Review in China
12th Dec 20198:57 amRNSGrant of share options
29th Nov 20198:56 amRNSTotal Voting Rights
28th Nov 20197:00 amRNSElunate® Included in China NRDL
25th Nov 20197:47 amRNSChi-Med Highlights Presentations at 2019 ESMO Asia
25th Nov 20197:00 amRNSSurufatinib granted FDA orphan drug designation
11th Nov 20197:00 amRNSSurufatinib China NDA acceptance
17th Oct 20197:26 amRNSChi-Med Ph II gastric cancer data for Savolitinib
10th Oct 201910:22 amRNSGrant of share options under share option scheme
10th Oct 20199:00 amRNSInnovent and Chi-Med Expand Global Collaboration
4th Oct 20197:11 amRNSChi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma
3rd Oct 20198:26 amRNSHolding(s) in Company
30th Sep 20191:49 pmRNSHolding(s) in Company
30th Sep 201912:11 pmRNSHolding(s) in Company
30th Sep 20197:00 amRNSChi-Med Surufatinib Phase III data at ESMO
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 20197:00 amRNSChi-Med Presents SANET-ep Phase III data at ESMO
18th Sep 20197:00 amRNSChi-Med Highlights Presentations at 2019 CSCO
3rd Sep 20197:19 amRNSChi-Med to present at MS conference
3rd Sep 20197:00 amRNSChi-Med initiates Phase I trial
30th Aug 20197:00 amRNSTotal Voting Rights
23rd Aug 20197:00 amRNSStart of Clinical Trial in China
20th Aug 20197:48 amRNSHolding(s) in Company
30th Jul 201910:48 amRNSTR-1: Form for notification of major holdings
30th Jul 20197:00 amRNS2019 Interim Results and Clinical Programs Update
10th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 20197:00 amRNSChi-Med to Announce 2019 Half-Year Results
3rd Jul 20197:00 amRNSTR-1: Form for notification of major holdings
28th Jun 201911:10 amRNSBlocklisting Six Monthly Return
28th Jun 201910:07 amRNSPricing of U.S. Public Secondary Offering of ADSs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.